Reduced Nephron Number in Adult Sheep, Hypertensive As a Result of Prenatal Glucocorticoid Treatment
Overview
Affiliations
There is some evidence, mainly from rodent studies, that any factor which alters the final total number of nephrons formed, during nephrogenesis, will result in hypertension in adult life. Sheep, programmed to become hypertensive by exposure to synthetic glucocorticoid (dexamethasone, 0.48 mg h-1, for 48 h) early in development (~27 days of gestation), were killed at 7 years of age, and had nephron counting performed by unbiased stereology. Mean arterial pressure was 83 +/- 4 mmHg in the dexamethasone (DEX) group (n = 5), and 73 +/- 5 in the control (CON; n = 7; P < 0.05). The total nephron number, in the right kidney (249 070 +/- 14 331; n = 5) was significantly lower (P < 0.01) than that of controls (402 787 +/- 30 458; n = 7). Mean glomerular volume was larger in the DEX than the CON group (P < 0.01), but there was no significant difference in the sclerosis index between the two groups. Low nephron number was associated with grossly enlarged and dilated proximal tubules and greater accumulation of collagen type I and type III in the tubular interstitium and periadventitia of the renal cortical vessels. These data suggest that the hypertensive programming effect of glucocorticoid treatment, early in kidney development, results, at least in part, from impaired nephrogenesis.
Respiratory distress syndrome is the poster child for neonatology.
Jobe A Pediatr Res. 2025; .
PMID: 39821130 DOI: 10.1038/s41390-024-03723-1.
Medina Munoz M, Canto Cerdan M, Matias Del Pozo V, Pino Vazquez A, Alcaraz Romero A, Tarraga Lopez P Pediatr Nephrol. 2025; .
PMID: 39775937 DOI: 10.1007/s00467-024-06631-y.
Prenatal glucocorticoids exposure and adverse cardiovascular effects in offspring.
Zhao C, He L, Li L, Deng F, Zhang M, Wang C Front Endocrinol (Lausanne). 2024; 15:1430334.
PMID: 39351527 PMC: 11439645. DOI: 10.3389/fendo.2024.1430334.
Guidelines for in vivo models of developmental programming of cardiovascular disease risk.
Warrington J, Collins H, Davidge S, do Carmo J, Goulopoulou S, Intapad S Am J Physiol Heart Circ Physiol. 2024; 327(1):H221-H241.
PMID: 38819382 PMC: 11380980. DOI: 10.1152/ajpheart.00060.2024.
Cabala S, Ozgo M, Herosimczyk A Metabolites. 2024; 14(1).
PMID: 38276313 PMC: 10819792. DOI: 10.3390/metabo14010078.